DCTH
Delcath Systems, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Delcath Systems, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Delcath Systems, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Delcath Systems, Inc.'s 6 closest co-movers, none share that code.
Delcath Systems, Inc.
14.36
+0.07 · +0.47%
post 14.39 +0.23%
+22.49%
vs ±15.9% implied · ×1.41
shaded = implied · ▲▼ = realized
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
—
—
| Manager | Value | % base | |
|---|---|---|---|
| Rosalind | $41.6M | 18.42% | 0.00% |
| BlackRockindex-like | $34.1M | 15.11% | +51.69% |
| Vanguardindex-like | $15.4M | 6.82% | −8.13% |
| Propel Bio | $11.0M | 4.86% | −11.05% |
| Geodeindex-like | $9.2M | 4.09% | +5.94% |
| Manager | Value | % base | |
|---|---|---|---|
| Rosalind | $41.6M | 18.42% | 0.00% |
| BlackRockindex-like | $34.1M | 15.11% | +51.69% |
| Vanguardindex-like | $15.4M | 6.82% | −8.13% |
| Propel Bio | $11.0M | 4.86% | −11.05% |
| Geodeindex-like | $9.2M | 4.09% | +5.94% |
Expected move
Inputsstraddle ±21.2%
spot 14.40exp Nov 20ATM strike 15ATM straddle 3.60IV 142%